Eli Lilly and Company (NYSE:LLY) Holdings Decreased by Rice Partnership LLC

Rice Partnership LLC lessened its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 18,757 shares of the company's stock after selling 1,495 shares during the period. Eli Lilly and Company comprises 3.2% of Rice Partnership LLC's portfolio, making the stock its 8th largest holding. Rice Partnership LLC's holdings in Eli Lilly and Company were worth $15,491,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Tradewinds LLC. boosted its holdings in shares of Eli Lilly and Company by 3.7% during the 1st quarter. Tradewinds LLC. now owns 6,002 shares of the company's stock valued at $4,957,000 after acquiring an additional 215 shares during the last quarter. Cloud Capital Management LLC bought a new stake in shares of Eli Lilly and Company in the first quarter worth $54,000. Argentarii LLC lifted its holdings in Eli Lilly and Company by 1.2% in the first quarter. Argentarii LLC now owns 4,744 shares of the company's stock valued at $3,918,000 after acquiring an additional 54 shares during the period. McGlone Suttner Wealth Management Inc. grew its stake in shares of Eli Lilly and Company by 37.0% during the 1st quarter. McGlone Suttner Wealth Management Inc. now owns 1,052 shares of the company's stock valued at $869,000 after purchasing an additional 284 shares during the period. Finally, Lee Danner & Bass Inc. lifted its stake in shares of Eli Lilly and Company by 4.7% in the 1st quarter. Lee Danner & Bass Inc. now owns 585 shares of the company's stock worth $483,000 after purchasing an additional 26 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 1.0%

LLY traded down $7.85 on Monday, reaching $772.82. 2,575,478 shares of the company traded hands, compared to its average volume of 3,663,617. The company has a market cap of $732.43 billion, a P/E ratio of 62.88, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The firm has a fifty day simple moving average of $773.61 and a two-hundred day simple moving average of $800.26.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same quarter in the prior year, the business posted $2.58 EPS. The business's quarterly revenue was up 45.2% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.78%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on LLY shares. Guggenheim reiterated a "buy" rating and issued a $936.00 price target on shares of Eli Lilly and Company in a research report on Friday, June 20th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. UBS Group dropped their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.